Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEnlivex Therapeutics Ltd

Enlivex Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.27 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
18108
Market Cap
15.43M

Momentum Score

…

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.23
Low
1.30
High
52 Week Price Range
0.86
Low
19.80
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Enlivex Therapeutics Ltd is a clinical-stage biotechnology company developing cell-based immunomodulatory therapies for severe inflammatory and immune-mediated conditions. Long-term growth may be supported by clinical advancement of lead candidates, regulatory progress and commercial adoption in high-unmet-need areas such as sepsis and ARDS. The company could appeal to investors for a differentiated mechanism addressing sizeable acute-care markets.
Key risks include typical clinical-stage biotech exposures: negative trial results or regulatory delays, significant financing and cash‑burn requirements, manufacturing and scale-up challenges, and competition from alternative therapies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.27
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
126.17%
Net Debt
-1.37M
ROCE
-0.65%
Diluted EPS TTM
385.30

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1618.17M -15.01M -29.07M -31.06M -14.47M
Net income 1235.53M -15.01M -29.07M -42.41M -9.65M
Selling general administrative 5.68M 4.91M 6.14M 6.70M 6.24M
Selling and marketing expenses - - 6.10M - -
Gross profit -0.33M -0.55M -0.83M - -
Reconciled depreciation 0.33M 0.55M 0.86M 0.78M 0.55M
Ebit -15.00M -15.01M -29.05M -25.80M -19.29M
Ebitda -14.67M -14.47M -28.22M -18.94M -23.77M
Depreciation and amortization 0.33M 0.55M 0.83M 6.86M -4.48M
Operating income -15.00M -15.54M -29.39M -25.80M -19.29M
Other operating expenses 15.00M 15.54M 29.39M 25.80M 19.29M
Interest expense 0.01M 0.01M 0.01M 5.26M 4.82M
Tax provision 382.65M 0.00M 0.00M - -
Interest income 0.79M 1.07M 1.56M 0.83M 0.12M
Net interest income 0.78M 1.06M 1.55M 0.82M -0.21M
Income tax expense 382.65M - 4.24M 11.35M -4.82M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 14.67M 14.99M 29.39M 25.80M 19.29M
Cost of revenue 0.33M 0.55M 0.83M - -
Total other income expense net 1633.17M 0.52M 0.33M -5.26M 4.82M
Net income from continuing ops 1235.53M -15.01M -27.16M -31.06M -14.47M
Net income applicable to common shares - - - -31.06M -14.47M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2327.00M 27.69M 36.83M 67.64M 95.15M
Intangible assets 582.51M - - - -
Other current assets 1737.08M 1.08M 6.33M 2.38M 12.32M
Total liab 392.05M 4.10M 6.75M 10.80M 10.11M
Total stockholder equity 1934.95M 23.59M 30.08M 56.84M 85.04M
Other current liab 4.96M 2.75M 4.89M 4.01M 3.22M
Common stock 28.73M 2.69M 2.14M 2.12M 2.11M
Capital stock 28.73M 2.69M 2.14M 2.12M 2.11M
Retained earnings 1108.42M -127.11M -112.09M -83.03M -51.97M
Other liab - - - - 5.39M
Other assets - - - 0.41M 6.17M
Cash 2.01M 3.30M 0.93M 47.82M 11.20M
Total current liabilities 9.02M 3.80M 6.06M 6.61M 4.72M
Net debt -1.37M -2.77M 0.11M -42.98M -10.59M
Short term debt 0.26M 0.23M 0.35M 0.65M 0.62M
Short long term debt total 0.64M 0.53M 1.03M 4.85M 0.62M
Other stockholder equity 796.70M 146.91M 138.94M 136.65M 133.80M
Property plant equipment - - - 14.90M 2.53M
Total current assets 1743.18M 25.99M 33.76M 52.33M 86.44M
Long term investments - - - - 0.00M
Net tangible assets - - - 56.84M 85.04M
Short term investments 3.86M 20.20M 26.51M 0.30M 72.93M
Net receivables 0.23M 1.30M 0.23M 0.65M 2.20M
Inventory - - -0.23M 1.18M -12.20M
Accounts payable 3.81M 0.81M 0.83M 1.95M 0.88M
Accumulated other comprehensive income 1.10M 1.10M 1.10M 1.10M 1.10M
Non currrent assets other 582.88M 0.01M 0.18M 0.41M 0.48M
Non current assets total 583.82M 1.69M 3.07M 15.31M 8.70M
Capital lease obligations 0.64M 0.53M 1.03M 0.65M 0.62M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1.26M 9.06M -32.98M 62.52M -36.78M
Change to liabilities - - - 1.17M 0.44M
Total cashflows from investing activities -1.32M 9.06M -25.97M 62.52M -38.41M
Total cash from financing activities 10.38M 6.45M 0.36M 0.15M 60.98M
Change to operating activities - - - -0.36M -1.80M
Net income 1235.53M -15.01M -29.07M -31.06M -14.47M
Change in cash -1.41M 2.50M -49.13M 38.72M 4.62M
Begin period cash flow 3.41M 1.23M 50.36M 11.64M 7.01M
End period cash flow 2.01M 3.73M 1.23M 50.36M 11.64M
Total cash from operating activities -10.42M -13.01M -23.52M -23.95M -17.54M
Issuance of capital stock 10.38M 6.45M 0.36M 0.00M 53.17M
Depreciation 0.33M 0.55M 0.83M 0.78M 0.55M
Other cashflows from investing activities 0.00M 2.29M 0.13M - -
Change to account receivables -3.05M 0.43M 0.61M - -
Other cashflows from financing activities - - -25.97M 0.15M 7.81M
Change to netincome - - - 5.53M -2.26M
Capital expenditures 0.07M 0.10M 0.24M 8.12M 1.62M
Change in working capital 0.81M -1.22M -1.82M 0.80M -1.36M
Stock based compensation 1.78M 2.06M 1.95M 2.71M 2.91M
Other non cash items -1631.52M 0.61M 4.58M 2.81M 0.41M
Free cash flow -10.48M -13.11M -23.76M -32.08M -19.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ENLV
Enlivex Therapeutics Ltd		 -
-%		 1.27 - - - 0.01 -1.49
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Enlivex Therapeutics Ltd

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

14 Einstein Street, Ness Ziona, Israel, 7403618

972 2 620 8072

https://www.enlivex.com

34

Name Title Year Born
Mr. Shai Novik M.B.A. Exec. Chairman 1966
Dr. Oren Hershkovitz Ph.D. Chief Exec. Officer 1977
Prof. Dror Mevorach M.D. Founder and Chief Scientific & Medical Officer 1956
Ms. Shachar Shlosberger CPA Chief Financial Officer 1977
Ms. Sigal Arad Director of HR NA
Mr. Veronique Amor-Baroukh Head Of CMC NA
Mr. Shai Novik M.B.A. Executive Chairman 1966
Dr. Oren Hershkovitz Ph.D. Chief Executive Officer 1977
Mr. Veronique Amor-Baroukh Senior Director of Operations NA
Prof. Dror Mevorach M.D. Founder & Scientific Advisor 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…